Davidson Investment Advisors raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,815 shares of the medical instruments supplier’s stock after buying an additional 542 shares during the period. Davidson Investment Advisors’ holdings in Becton, Dickinson and were worth $6,200,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Raymond James Trust N.A. raised its stake in shares of Becton, Dickinson and by 3.5% in the first quarter. Raymond James Trust N.A. now owns 5,846 shares of the medical instruments supplier’s stock valued at $1,073,000 after buying an additional 200 shares during the period. Northstar Group Inc. raised its stake in shares of Becton, Dickinson and by 0.3% in the first quarter. Northstar Group Inc. now owns 2,985 shares of the medical instruments supplier’s stock valued at $550,000 after buying an additional 10 shares during the period. Cardinal Capital Management Inc. acquired a new stake in shares of Becton, Dickinson and during the first quarter valued at about $14,321,000. Confluence Investment Management LLC raised its stake in shares of Becton, Dickinson and by 6.1% in the first quarter. Confluence Investment Management LLC now owns 79,474 shares of the medical instruments supplier’s stock valued at $14,579,000 after buying an additional 4,569 shares during the period. Finally, Fulton Bank N.A. raised its stake in shares of Becton, Dickinson and by 0.9% in the first quarter. Fulton Bank N.A. now owns 2,706 shares of the medical instruments supplier’s stock valued at $496,000 after buying an additional 24 shares during the period. Institutional investors own 75.61% of the company’s stock.
Shares of Becton, Dickinson and Company (BDX) traded down 0.27% during trading on Friday, reaching $198.36. 121,747 shares of the company’s stock traded hands. The stock has a market cap of $42.31 billion, a P/E ratio of 32.94 and a beta of 1.05. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $206.63. The company has a 50 day moving average price of $197.67 and a 200-day moving average price of $186.53.
Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 10.67% and a return on equity of 25.37%. The business’s revenue was down 5.1% on a year-over-year basis. During the same quarter last year, the company earned $2.35 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post $9.45 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.47%. Becton, Dickinson and’s payout ratio is 48.26%.
TRADEMARK VIOLATION NOTICE: “Davidson Investment Advisors Acquires 542 Shares of Becton, Dickinson and Company (NYSE:BDX)” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/08/04/davidson-investment-advisors-acquires-542-shares-of-becton-dickinson-and-company-nysebdx.html.
Several analysts recently issued reports on the stock. Bank of America Corporation restated a “buy” rating and set a $225.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. BidaskClub lowered shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a research report on Monday, July 17th. Cowen and Company restated an “outperform” rating and set a $230.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. Finally, Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and cut their target price for the company from $210.00 to $180.00 in a research report on Friday, June 30th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $194.69.
In other news, VP Jeffrey S. Sherman sold 28,765 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the sale, the vice president now owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.40% of the stock is owned by company insiders.
About Becton, Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
